Review
doi: 10.1016/j.hoc.2014.02.001.
Epub 2014 Apr 3.
Interferon, interleukin-2, and other cytokines
Affiliations
- PMID: 24880948
- DOI: 10.1016/j.hoc.2014.02.001
Item in Clipboard
Review
Interferon, interleukin-2, and other cytokines
Hematol Oncol Clin North Am.
2014 Jun.
Abstract
Cytokines are a diverse group of signaling molecules with immunomodulatory activity. This article reviews the application of cytokine therapy in melanoma with a focus on interferon-α and interleukin-2. In addition, it addresses the clinical considerations of these therapies including patient selection, reduction in toxicity, and combination regimens.
Keywords: Cytokines; Granulocyte-macrophage colony–stimulating factor; Interferon; Interleukin-2; Interleukin-21; Melanoma.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Cytokine therapy in advanced melanoma.J Drugs Dermatol. 2007 Apr;6(4):374-8. J Drugs Dermatol. 2007. PMID: 17668534 Review.
-
Chemotherapy, cytokines, and biochemotherapy for melanoma.Cancer Chemother Biol Response Modif. 2005;22:739-48. Cancer Chemother Biol Response Modif. 2005. PMID: 16110637 Review. No abstract available.
-
Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:238-47. Gan To Kagaku Ryoho. 2000. PMID: 10895160 Review. No abstract available.
-
Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.Clin Cancer Res. 2000 Oct;6(10):4167. Clin Cancer Res. 2000. PMID: 11051273 No abstract available.
-
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.Melanoma Res. 2009 Apr;19(2):100-5. doi: 10.1097/CMR.0b013e328328f7ec. Melanoma Res. 2009. PMID: 19262411 Clinical Trial.
Cited by
-
Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.Oncoimmunology. 2017 Feb 17;6(3):e1290038. doi: 10.1080/2162402X.2017.1290038. eCollection 2017. Oncoimmunology. 2017. PMID: 28405526 Free PMC article.
-
VEGFR2-targeted antibody fused with IFN α mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity.Acta Pharm Sin B. 2021 Feb;11(2):420-433. doi: 10.1016/j.apsb.2020.09.008. Epub 2020 Sep 19. Acta Pharm Sin B. 2021. PMID: 33643821 Free PMC article.
-
Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov.Front Pharmacol. 2020 Jan 10;10:1539. doi: 10.3389/fphar.2019.01539. eCollection 2019. Front Pharmacol. 2020. PMID: 31998135 Free PMC article.
-
The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs).J Immunol Res. 2022 Mar 26;2022:2054431. doi: 10.1155/2022/2054431. eCollection 2022. J Immunol Res. 2022. PMID: 35378905 Free PMC article. Review.
-
Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma.Signal Transduct Target Ther. 2023 Oct 6;8(1):382. doi: 10.1038/s41392-023-01611-4. Signal Transduct Target Ther. 2023. PMID: 37798307 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
